Apogee Therapeutics, Inc. Common Stock (APGE) Stock Forecast & Price Target
Apogee Therapeutics, Inc. Common Stock · NASDAQ
$135.07+0.00 (+0.00%)
15-min delayed · Sep 3, 8:00 AM ET · Get real-time quotes →
The Quantellect read.Of the 16 firms covering Apogee Therapeutics, Inc. Common Stock, 3 rate it Buy or better, 13 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $95.00 to $160.00, a moderate spread. The average target of $132.59 sits 2% below the current $135.07. The rating mix has stayed broadly stable, with Buy-side ratings easing from 5 to 3 over recent months. On the fundamentals, the Street sees revenue growth near 0% this year and 0% next, consensus EPS building from about $-1.37 next quarter toward $-5.20 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS16 ratings
Moderate Buy
Strong Buy00%
Buy319%
Hold1381%
Sell00%
Strong Sell00%
Based on 16 analysts giving stock ratings to Apogee Therapeutics, Inc. Common Stock.
As of Sep, 3 of 16 firms rate APGE a Buy (13 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
APGE EPS & revenue forecast
EPS · NEXT QUARTER
$-1.37
Range $-1.40 – $-1.34 · 2 analysts · +33% YoY
Next period, 2 analysts expect Apogee Therapeutics, Inc. Common Stock to earn $-1.37 a share (range $-1.40 – $-1.34), versus $-1.03 a year earlier. Full-year consensus is $-4.86, growing to $-5.20 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 2 analysts · +0% YoY
Revenue is expected to reach $0 (range $0 – $0), +0.0% year-over-year. Full-year consensus is $0, rising to $7.1M next year.
Top analysts covering Apogee Therapeutics, Inc. Common Stock
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on APGE.
#1
David Nierengarten
Wedbush · Rank #66
Hold
$135.00-0.1% to target
Overall win rate
42%
+ Follow
#2
TA
Tazeen Ahmad
B of A Securities · Rank #317
Buy
$131.00-3.0% to target
Overall win rate
47%
+ Follow
#3
Brian Abrahams
RBC Capital · Rank #371
Hold
$135.00-0.1% to target
Overall win rate
28%
+ Follow
#4
Julian Harrison
BTIG
Hold
No targeton APGE
Coverage
—
+ Follow
#5
Seamus Fernandez
Guggenheim
Hold
No targeton APGE
Coverage
—
+ Follow
APGE stock forecast FAQ
What is APGE's average 12-month price target?+
The 12 analysts with a live target average $132.59 for Apogee Therapeutics, Inc. Common Stock over the next 12 months, ranging from a $160.00 high to a $95.00 low.
Is APGE stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 16 analyst ratings, 3 are Buy or Strong Buy, 13 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for APGE?+
The Street-high target is $160.00, and the Street-low is $95.00 (Stephens & Co.). The average of all 12 active targets is $132.59.
How many Wall Street analysts cover APGE?+
16 analysts have an active rating on Apogee Therapeutics, Inc. Common Stock, and 12 firms carry a live 12-month price target.
Who is the most accurate analyst covering APGE?+
Among analysts who currently cover APGE, David Nierengarten of Wedbush has the strongest overall Quantellect track record (Rank #66). Their current call is Hold with a $135.00 target.
What is Apogee Therapeutics, Inc. Common Stock's projected EPS for next quarter?+
The consensus estimate is $-1.37 per share (range $-1.40 – $-1.34) across 2 analysts. Full-year EPS is projected at $-4.86, rising to $-5.20 the following year.
How much revenue is Apogee Therapeutics, Inc. Common Stock expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $7.1M next year.
Have analysts been upgrading or downgrading APGE lately?+
As of Sep, 3 of 16 firms rate APGE a Buy (13 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their APGE calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
